Lidocaine and dibucaine
This article was originally published in The Tan Sheet
Executive Summary
NDMA asks Consumer Products Safety Commission to reconsider its proposal to require child-resistant packaging for lidocaine- and dibucaine-containing products in a July 6 letter. Based on 1987-1991 data from the American Association of Poison Control Centers, NDMA said there have been 2,683 reported ingestions of lidocaine by children under six years old and no deaths, and 535 dibucaine ingestions resulting in two deaths. NDMA estimated that "about 50 mil." packages of lidocaine- and dibucaine-containing OTC anesthetics were sold from 1987 to 1991. A briefing package on topical lidocaine/dibucaine child-safety caps is expected to be issued to CPSC commissioners for consideration in September ("The Tan Sheet" July 26, p. 12).
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning